# Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer

> **NCT05908747** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 29 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** surufatinib + gemcitabine + nab-paclitaxel

## Key facts

- **NCT ID:** NCT05908747
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-31
- **Primary completion:** 2025-05-16
- **Final completion:** 2026-05
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05908747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05908747, "Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05908747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*